Key result
Septal myectomy improves ~71% of HCM patients to NYHA class I.
Why the study?
Septal myectomy is often required for drug-refractory obstructive hypertrophic cardiomyopathy, but few centers in Colombia have experience with the procedure.
Does septal myectomy improve clinical and echocardiographic outcomes in patients with hypertrophic cardiomyopathy?
Cohort (n=18)
No
Does septal myectomy improve clinical and echocardiographic outcomes in patients with hypertrophic cardiomyopathy?
Septal myectomy is a safe procedure that provides clinical and echocardiographic improvement in patients with hypertrophic cardiomyopathy in a Colombian cohort.
May support myectomy for symptom relief in HCM; leaves open need for randomized confirmation beyond this cohort.
Hypertrophic cardiomyopathy (HCM) with left ventricular outflow tract obstruction that doesn't improve with pharmacological management often requires septal myectomy. However, there are few centers with experience in the practice of this procedure in our country. We describe the clinical and echocardiographic characteristics and postoperative outcomes of patients with HCM indicated for septal myectomy at a reference center in Colombia. MATERIALS AND METHODS: Retrospective cohort study. Patients undergoing septal myectomy between 2010 and 2023 were included. Data were collected before and two years after surgery. RESULTS: 18 patients were included. The mean age was 50 years. The predominant functional class was NYHA II/III (94 %). Asymmetric septal variant (83.3 %) was the most frequent as well as obstructive phenotype (88.8 %). After myectomy, 70.5 % improved to NYHA I and 62.4 % had no significant gradient (<30 mmHg), and the most of patient improved SAM. One patient died post-procedure, anymore complications were presented. DISCUSSION/CONCLUSIONS: Septal myectomy is a safe procedure, with clinical and echocardiographic improvement, with low complication rates.
No takes yet. Share an insight, caveat, or question.
Lopez-Gutierrez et al. (2024) conducted a cohort in Hypertrophic cardiomyopathy (n=18). Septal myectomy was evaluated on Improvement to NYHA class I. Septal myectomy in patients with hypertrophic cardiomyopathy resulted in 70.5% improving to NYHA class I and 62.4% achieving a non-significant gradient (<30 mmHg) postoperatively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: